69 results on '"Roobol, Monique J."'
Search Results
2. PD11-10 COMPLICATIONS AFTER TRANSPERINEAL PROSTATE BIOPSY WITHOUT ANTIBIOTIC PROPHYLAXIS: A CONTRIBUTION TO THE EFFORT TO CONTROL THE SPREAD OF ANTIBIOTICS RESISTANCE
3. MP09-04 A UNIQUE COMPARISON OF PROSTATE CANCER DETECTION RATES BETWEEN TRANSRECTAL VERSUS TRANSPERINEAL MRI-TRUS FUSION PROSTATE BIOPSY AMONG 794 CASES
4. PD13-04 PROSTATE CANCER SPECIFIC MORTALITY IN THE ERSPC TRIAL: WHAT IS THE ROLE OF SCREENING RESULT AND ADHERENCE
5. Risk-Based Selection for Active Surveillance: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative
6. Reply by Authors
7. Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer
8. Optimal Timing of Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Biochemical Recurrence after Radical Prostatectomy
9. Reply by Authors
10. PD48-03 PROSTATE CANCER SCREENING WITH PSA, PROSTATE HEALTH INDEX AND MRI IN A PROSPECTIVE COHORT OF HONG KONG CHINESE MEN: AN INTERIM ANALYSIS
11. Prostate Carcinoma Grade and Length But Not Cribriform Architecture at Positive Surgical Margins Are Predictive for Biochemical Recurrence After Radical Prostatectomy
12. PD64-02 THE RELATION BETWEEN BASELINE PSA, CANCER DETECTION AND PC DEATH, LONG-TERM DATA FROM ERSPC
13. Editorial Comment
14. Improving the evaluation and diagnosis of clinically significant prostate cancer in 2017
15. MP77-13 A PROSPECTIVE EVALUATION ON THE EFFECT OF INTER-OBSERVER VARIABILITY OF DRE ON THE PERFORMANCE OF THE DRE BASED ROTTERDAM PROSTATE CANCER RISK CALCULATOR
16. Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above
17. What's new in screening in 2015?
18. PD08-04 VALIDATION OF A RISK CALCULATOR PREDICTING BIOPSY OUTCOME IN PROSTATE CANCER TREATED WITH ACTIVE SURVEILLANCE
19. PD09-01 CORRELATION BETWEEN STAGE SHIFT AND DIFFERENCES IN MORTALITY BETWEEN THE TWO STUDY ARMS OF THE ERSPC.
20. Do Treatment Differences between Arms Affect the Main Outcome of ERSPC Rotterdam?
21. Value of 3-T Multiparametric Magnetic Resonance Imaging and Magnetic Resonance–Guided Biopsy for Early Risk Restratification in Active Surveillance of Low-Risk Prostate Cancer
22. Active surveillance
23. 1932 SCREENING FOR PROSTATE CANCER: RESULTS OF THE ROTTERDAM SECTION OF THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER (ERSPC)
24. 2054 REDUCING UNNECESSARY BIOPSIES FOR SUSPICION OF PROSTATE CANCER: EXTENSION AND VALIDATION OF AN ERSPC BASED RISK CALCULATOR WITH PHI AND COMPARISON WITH THE PCPT RISK CALCULATOR INCLUDING %FREE AND -2PROPSA
25. Contemporary role of prostate cancer gene 3 in the management of prostate cancer
26. 2033 DISEASE-SPECIFIC SURVIVAL IN MEN WITH INTERVAL CANCERS COMPARED TO MEN WITH CANCERS IN THE CONTROL ARM: LONG-TERM RESULTS OF THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER (ERSPC)-ROTTERDAM
27. 1922 COMPARISON OF RISK CALCULATORS FROM THE PROSTATE CANCER PREVENTION TRIAL AND THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER IN A CONTEMPORARY CANADIAN COHORT
28. 2028 “ESCAPES”-MEN WHO DEVELOP METASTASIS AND/OR DIE FROM PROSTATE CANCER DESPITE SCREENING-: LONG-TERM RESULTS FROM THE ERSPC, SECTION ROTTERDAM
29. A Critical Analysis of the Tumor Volume Threshold for Clinically Insignificant Prostate Cancer Using a Data Set of a Randomized Screening Trial
30. Screening for prostate cancer: have we resolved the controversy?
31. Prostate Specific Antigen Velocity Does Not Aid Prostate Cancer Detection in Men With Prior Negative Biopsy
32. Do Anxiety and Distress Increase During Active Surveillance for Low Risk Prostate Cancer?
33. 1982 HEAD TO HEAD COMPARISON OF THE ERSPC RISK CALCULATOR AND ANN PROSTATACLASS IN 4685 PATIENTS FOR PROSTATE CANCER RISK ON BIOPSY
34. 1840 PROSTATE VOLUME ADJUSTMENT WITH RECTAL EXAMINATION (DRE) WITHIN THE ERSPC RISK CALCULATOR
35. 2124 PREDICTING PROSTATE BIOPSY OUTCOME IN A SCREENING SETTING. PSA, PCA3, A KALLIKREIN PANEL, THE RISKCALCULATOR OR A COMBINATION? ERSPC ROTTERDAM
36. A Framework for the Identification of Men at Increased Risk for Prostate Cancer
37. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer
38. SECONDARY ANALYSIS OF THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER (ERSPC) - EFFECT OF PROSTATE CANCER SCREENING ON THE DEVELOPMENT OF METASTASES AFTER ADJUSTMENT FOR NON-COMPLIANCE AND CONTAMINATION
39. DEFINING MEN AT INCREASED RISK OF DEVELOPING PROSTATE CANCER: EVIDENCE FROM A POPULATION-BASED SCREENING COHORT
40. PC DETECTION IN MEN WITH INITIAL PSA LEVELS < 3.0 NG/ML. DATA FROM ERSPC 1993- 2007
41. ANXIETY AND DISTRESS DURING ACTIVE SURVEILLANCE FOR EARLY PROSTATE CANCER: A LONGITUDINAL ANALYSIS
42. MISSING A PROSTATE CANCER LESION DURING HISTOLOGICAL EXAMINATION OF PROSTATE BIOPSY: CHARACTERISTICS AND FOLLOW-UP IN A SCREENED COHORT
43. METASTASIS-FREE SURVIVAL IN SCREEN AND CLINICAL DETECTED PROSTATE CANCER: A COMPARISON BETWEEN THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER AND NORTHERN IRELAND
44. INDEPENDENT REPLICATION OF A FOUR KALLIKREIN PANEL TO DETECT PROSTATE CANCER: DATA FROM THE EUROPEAN RANDOMIZED STUDY OF PROSTATE CANCER SCREENING IN ROTTERDAM, NETHERLANDS
45. PROSPECTIVE PROTOCOL BASED ACTIVE SURVEILLANCE FOR EARLY PROSTATE CANCER: SHORT-TERM RESULTS OF 500 PATIENTS IN THE PRIAS STUDY
46. Defining Increased Future Risk for Prostate Cancer: Evidence From a Population Based Screening Cohort
47. VALUE OF PSA VELOCITY FOR PREDICTING BIOPSY OUTCOME IN PREVIOUSLY SCREENED MEN PARTICIPATING IN THE EUROPEAN RANDOMIZED STUDY OF PROSTATE CANCER SCREENING (ERSPC)
48. OVERALL VERSUS DISEASE-SPECIFIC SURVIVAL OF SCREEN- DETECTED PROSTATE CANCER PATIENTS WHO WERE INITIALLY MANAGED EXPECTANTLY
49. THE CLINICAL IMPACT OF THE PSA ASSAY WHO CALIBRATION ON PROSTATE BIOPSY RATES AND PROSTATE CANCER DETECTION
50. THE USE OF -2proPSA AND BPSA IN PROSTATE CANCER DETECTION: EXTERNAL CROSS-VALIDATION OF A PREDICTIVE MODEL
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.